Trigeminal Neuralgia Market Size in 7MM is expected to witness a major change in the study period 2019-2032 | Major Companies- Novartis, Biogen, Biohaven Pharmaceuticals, and Others

DelveInsight's "Trigeminal Neuralgia Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Trigeminal Neuralgia, historical and forecasted epidemiology as well as the Trigeminal Neuralgia market trends in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

Key Takeaways from the Trigeminal Neuralgia Market
• As per the National Organization for Rare Disorders (NORD), trigeminal neuralgia affects females slightly more often than males. Although the exact incidence is unknown, approximately 10,000-15,000 new cases occur each year in the United States.
• A study conducted by Obermann et al. in Germany titled "Treatment options in trigeminal neuralgia," indicated that the incidence of trigeminal neuralgia (TN) is 4.3 per 100,000 persons per year, with a slightly higher incidence for women (5.9 per 100,000) as compared to men (3.4 per 100,000). There is a lack of certainty regarding the etiology and pathophysiology of TN.
• The leading Trigeminal Neuralgia Market Companies include Amgen, Capnia, Inc., Noema Pharma AG, Biohaven Pharmaceuticals, Inc, and others
• Promising Trigeminal Neuralgia Therapies include Basimglurant, CNV1014802, Rimegepant, BIIB074, Erenumab-Aooe, and others.

Request a sample and discover the recent breakthroughs happening in the Trigeminal Neuralgia Pipeline landscape @ Trigeminal Neuralgia Pipeline Outlook Report- https://www.delveinsight.com/sample-request/trigeminal-neuralgia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Trigeminal Neuralgia Overview
Trigeminal Neuralgia (TN), also known as tic douloureux, is a chronic pain condition that affects the trigeminal or fifth cranial nerve, one of the most widely distributed nerves in the head. It is a form of neuropathic pain (pain associated with nerve injury or nerve lesion) and is categorized in two types: primary (idiopathic) and secondary.

Trigeminal Neuralgia Epidemiology Segmentation in the 7MM
• Trigeminal Neuralgia Incident Cases
• Trigeminal Neuralgia Gender Specific Incident Cases
• Trigeminal Neuralgia Age-Specific Incident Cases

For further information, refer to the detailed Trigeminal Neuralgia Drugs Launch, Trigeminal Neuralgia Developmental Activities, and Trigeminal Neuralgia News, click here for Trigeminal Neuralgia Ongoing Clinical Trial Analysis- https://www.delveinsight.com/sample-request/trigeminal-neuralgia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Trigeminal Neuralgia Treatment Market
The first line of treatment for patients with trigeminal neuralgia is always medication. The drugs most commonly used for treating trigeminal neuralgia are medications that were originally developed for the treatment of epilepsy. However, this class of medications has been found to be quite effective in treating nerve pain, including TN, when taken on an on-going basis. The anti-convulsant most commonly prescribed for TN is carbamazepine (Tegretol), which can provide at least partial pain relief for up to 80% to 90% of patients. Other anti-convulsants prescribed frequently for TN include phenytoin (Dilantin), gabapentin (Neurontin), lamotrigine (Lamictal), oxcarbazepine (Trileptal), and topiramate (Topamax). The muscle relaxant baclofen (Lioresal) can also be prescribed, alone or in combination with other drugs.

Trigeminal Neuralgia Market Insights
To counter unmet market needs and provide better treatment choices for TN, several market players are working robustly either on single-agent novel molecules or on combination and dose modification of standard therapies. Several therapies are expected to be launched in the study period, likely to drive market growth during the study period. A few major market players in Trigeminal Neuralgia market include Noema Pharma AG, Biohaven Pharmaceuticals, among others.

Find out more about the Trigeminal Neuralgia Pipeline Segmentation, Therapeutics Assessment, and Trigeminal Neuralgia Emerging Drugs @ Trigeminal Neuralgia Treatment Landscape- https://www.delveinsight.com/sample-request/trigeminal-neuralgia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Trigeminal Neuralgia Market Dynamics
The dynamics of Trigeminal Neuralgia (TN) market is expected to change due to the improvement in the diagnosis, incremental healthcare expenditure across the world and expected launch of emerging therapies during the forecast period of 2019─2032. Companies all over the globe are persistently working toward the development of new treatment therapies, such as Noema Pharma AG, Biohaven Pharmaceuticals and others.

Recent Developmental Activities in the Trigeminal Neuralgia Treatment Landscape
• In November 2021, Biohaven Pharmaceutical and Pfizer Inc. announced a strategic commercialization arrangement for rimegepant in markets outside of the United States upon approval.
• In July 2013, vixotrigine FDA granted orphan drug designation for the treatment of trigeminal neuralgia.
• Currently, the drug is being evaluated in Phase II of its clinical trial for the treatment of refractory trigeminal neuralgia.

Explore more information about the Trigeminal Neuralgia Drugs News, Breakthroughs, and Recent Developmental Activities of the disease @ https://www.delveinsight.com/sample-request/trigeminal-neuralgia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Trigeminal Neuralgia Market Report
• Coverage- 7MM
• Study Period- 2019-2032
• Trigeminal Neuralgia Companies- Amgen, Capnia, Inc., Noema Pharma AG, Biohaven Pharmaceuticals, Inc, and others
• Trigeminal Neuralgia Therapies- Basimglurant, CNV1014802, Rimegepant, BIIB074, Erenumab-Aooe, and others.
• Trigeminal Neuralgia Market Dynamics: Trigeminal Neuralgia Market Drivers and Barriers

Dive deep into rich insights for drugs for Trigeminal Neuralgia Pipeline Companies and Therapies, click here @ Trigeminal Neuralgia Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/trigeminal-neuralgia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Key Insights
2. Executive Summary of Trigeminal Neuralgia
3. Competitive Intelligence Analysis for Trigeminal Neuralgia
4. Trigeminal Neuralgia: Market Overview at a Glance
5. Trigeminal Neuralgia: Disease Background and Overview
6. Patient Journey
7. Trigeminal Neuralgia Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Trigeminal Neuralgia Unmet Needs
10. Key Endpoints of Trigeminal Neuralgia Treatment
11. Trigeminal Neuralgia Marketed Products
12. Trigeminal Neuralgia Emerging Therapies
13. Trigeminal Neuralgia: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Trigeminal Neuralgia
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight

Got Queries? Find out the related information on Trigeminal Neuralgia Mergers and acquisitions, Trigeminal Neuralgia Licensing Activities @ Trigeminal Neuralgia Recent Trends, and Future Perspectives- https://www.delveinsight.com/sample-request/trigeminal-neuralgia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.